|
March 2006
2006-03-28: RNAi Works In Monkeys
Liposome system delivers short RNAs, gene silencing, and sustained cholesterol reduction
Reported by Celia Henry Arnaud
The gene-silencing technique RNA interference has moved a step closer to becoming a viable therapeutic approach. Scientists at Alnylam Pharmaceuticals in Cambridge, Mass., used RNAi in monkeys to silence the gene for apolipoprotein B (ApoB), a protein involved in cholesterol metabolism. The study was published in the online edition of Nature on Sunday (Nature, published online March 26, dx.doi.org/10.1038/nature04688). Muthiah Manoharan, vice president for drug discovery at Alnylam, also described the work on Monday in a symposium sponsored by the Division of Medicinal Chemistry at the ACS national meeting in Atlanta.
Double
stranded RNAi help Mosquitoes resistent to Dengue Fever Virus
Anthony James, a UC Irvine vector biologist, is one of a team of researchers who injected
DNA into mosquito embryos, creating the first stable transgenic mosquito resistant to
Type 2 dengue fever virus, the most prevalent strain of the disease.
The mosquitoes that survived the procedure also remained fertile and were able to reproduce,
a key factor for any future strategies that may involve replacing mosquito populations
with their genetically modified counterparts.03-09-2006
www.sciencedaily.com
The
RNAi Market Achieved $1bn in 2004
2006-03-09-The RNAi market achieved global sales of just over $1bn in 2004
and is projected to reach $2.5bn by 2010, a compound annual growth
rate (CAGR) 2004-2010 of 14%. Research
and Markets has announced the addition of The Outlook for RNAi:
Accelerating Drug Discovery and the Development of RNAi Therapeutics
to their offering.
www.researchandmarket.com
RNAi
Screening of drug targets for obesity and diabete
2006-03-06- CytRx Corporation today announced the publication of a scientific
article in PNAS that further supports the use of the proprietary
RNA interference (RNAi) screening technology it has licensed in identifying
and validating novel drug targets for the development of therapeutics
to treat obesity and type 2 diabetes. The article reports that silencing
of these drug targets in fat cells enhances glucose transport and
insulin responsiveness, both of which are linked to obesity and type
2 diabetes. CytRx has exclusive rights to intellectual property covering
these drug targets and the RNAi screening method used to identify
them.
www.pharmaLive.com
Pioneers
of RNAi technology have been honored
The pioneers of somatic cell nuclear transfer, creators of Dolly in
1997, have been nominated for their contributions to the development
of key biotechnologies. Andrew Fire, Craig Mello and Tom Tuschl. For
invention and application of RNAi in mammalian cells have been nominated
as Honorable mentions. 2006-03-04
www.nature.com
Nastech
Takes Aim at Bird Flu with RNAi
Nastech Pharmaceutical Co., which has a manufacturing facility in
Hauppauge, acquired a division of intellectual properties from Galenea,
a Cambridge, Mass.-based biotech company to exploit Galenea’s research
in RNAi, or Ribonucleic Acid Interference, to prevent multiple strains
of the flu, including H5N1 in animals. 2006-03-03
www.redorbit.com
February 2006
Novartis and Alnylam Announce New Collaboration to Develop RNAi Therapeutics
f or Pandemic Flu
Novartis and Alnylam Pharmaceuticals, Inc. announced today the formation
of a new collaboration to develop therapeutics for pandemic flu based
on RNA interference (RNAi).2006-02-26
www.medicalnewstoday.com
March 2005
2005-03-24: 80 key genes invovled in RNAi discovered in MGH
A research team based at Massachusetts General Hospital (MGH) has
identified 80 new genes essential to the process of RNA interference
(RNAi), a powerful new research tool for inactivating genes in plants
or animals. They used the RNAi process itself to find new genes that
participate in the gene-silencing mechanism, which someday may help
to fight human disease. The report has been published in the journal
Science.
2005-03-16: $18M
open access RNAi library annouced
Eleven leading biomedical organizations including MIT, Harvard announced
today the formation of a unique $18M, three-year public-private consortium
to create a comprehensive library of gene inhibitors to be made available
to the entire scientific community. Based on the method of RNA interference
(RNAi), this library will give scientists worldwide the tools to knock
down expression of virtually all human and mouse genes, accelerating
the growth of basic knowledge of gene function in normal physiology
and disease.
2005-03-14: Oxford BioMedica's success on animal ALS with LentiVector-RNAi
OxfordBiomedica
| Nature
Medicine
Oxford BioMedica (LSE:OXB.L), the leading gene therapy company, announced
today the publication, in the journal Nature Medicine, of a paper
demonstrating efficacy of the Company’s LentiVector technology in
an animal model of inherited (familial) amyotrophic lateral sclerosis
(ALS) or motor neuron disease. The paper describes the delivery, by
the LentiVector technology, of a specific RNAi molecule that shuts
down the gene that causes the disease.
Back to top
|